Ligand Pharmaceuticals LGND Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's total costs & expenses?
- Ligand Pharmaceuticals (LGND) reported total costs & expenses of $34.35M in Q1 2026.
- How has Ligand Pharmaceuticals's total costs & expenses changed year-over-year?
- Ligand Pharmaceuticals's total costs & expenses decreased by 57.9% year-over-year, from $81.55M to $34.35M.
- What is the long-term trend for Ligand Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's total costs & expenses has grown at a 13.3% compound annual growth rate (CAGR), from $137.69M to $227.09M.
- What does total costs & expenses mean?
- This represents the aggregate sum of all operating and non-operating costs incurred by the company to support its business activities during a specific period. It includes cost of goods sold, research and development, selling, general and administrative expenses, and other operational outlays. This figure is a critical indicator of the company's overall cost structure and operational scale.